SEC For		_															
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STATEMENT OF CHANGES IN BENEFICIAL OWNI Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP	Estim	OMB Number: 3 Estimated average burder hours per response:		3235-0287 en 0.5	
I	nd Address of EMAN E	k		2. Issuer Name and Ticker or Trading Symbol Bolt Biotherapeutics, Inc. [BOLT]							Relationship leck all appli X Directo	cable)	ıg Perso	ssuer			
(Last)						3. Date of Earliest Transaction (Month/Day/Year) Off							Officer (give title Other (spe below) below)				
C/O BOLT BIOTHERAPEUTICS 900 CHESAPEAKE DRIVE			, INC.		4. If Ame	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) REDWC CITY	OOD C.	CA 94063			Rule 10b5-1(c) Transaction Indication									d by More than One Reporting			
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Noi	ו-Deriv	ative Se	curities Ac	quired,	Disp	osed o	of, or Be	eneficia	lly Owned	b				
Da			2. Trans Date (Month/I	Day/Year) i	2A. Deemed Execution Date, f any Month/Day/Yea	Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) ((D)	Price	Transac (Instr. 3	tion(s)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution ity or Exercise (Month/Day/Year) if any		Date, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date E Expiratio (Month/D	n Date		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	iy D (I)	D. wnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)		

Date Exercisable

(1)

(D)

1. The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

25,000

Expiration Date

06/11/2033

Title

Common Stock

<u>/s/ William P. Quinn, Attorney-</u> <u>in-Fact</u> <u>06/14/2023</u>

\$0.00

25,000

D

** Signature of Reporting Person Date

Amount or Number

of Shares

25,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/12/2023

Stock Option (Right to Buy)

Remarks:

\$1<mark>.63</mark>

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V (A)

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.